Friday, April 26, 2019 5:23:54 AM
Health Canada Clinical Trial Authorization (“CTA”)Complete, Investigational Testing Authorization (“ITA”)Complete. Clinical Site Review Ethics Board (“REB”)Pending- Approval to Commence Enrolling and Treating Patients in Canada 2Q2019 Completed!!!
Theralase Commences Phase II NMIBC Clinical Study
FDA Investigational New Drug (“IND”) and European IND Approval to Commence Enrolling and Treating Patients in the United States and Europe 3Q2019
Enroll, Treat and Follow-Up Approximately 100 NMIBC Patients in Canada, the United States and Europe 2Q2019 to 4Q2021
http://theralase.com/wp-content/uploads/2019/03/Theralase-Corporate-Power-Point-Presentation-03-25-2019.pdf
JMO, maybe, maybe not.
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM